Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Common Equity: 2020-2024

Historic Common Equity for Autolus Therapeutics (AUTL) over the last 5 years, with Dec 2024 value amounting to $427.3 million.

  • Autolus Therapeutics' Common Equity fell 44.35% to $265.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $265.5 million, marking a year-over-year decrease of 44.35%. This contributed to the annual value of $427.3 million for FY2024, which is 283.34% up from last year.
  • As of FY2024, Autolus Therapeutics' Common Equity stood at $427.3 million, which was up 283.34% from $111.5 million recorded in FY2023.
  • In the past 5 years, Autolus Therapeutics' Common Equity ranged from a high of $427.3 million in FY2024 and a low of $111.5 million during FY2023.
  • Over the past 3 years, Autolus Therapeutics' median Common Equity value was $298.7 million (recorded in 2022), while the average stood at $279.2 million.
  • As far as peak fluctuations go, Autolus Therapeutics' Common Equity tumbled by 62.68% in 2023, and later soared by 283.34% in 2024.
  • Yearly analysis of 5 years shows Autolus Therapeutics' Common Equity stood at $210.0 million in 2020, then spiked by 49.18% to $313.3 million in 2021, then declined by 4.67% to $298.7 million in 2022, then crashed by 62.68% to $111.5 million in 2023, then skyrocketed by 283.34% to $427.3 million in 2024.